J&J pays $6.5bn for Momenta and its inflammatory disease hopefulJohnson & Johnson is to buy Momenta Pharmaceuticals for $6.5 billion, adding potential inflammatory diseases blockbuster nipocalimab to Share XJ&J pays $6.5bn for Momenta and its inflammatory disease hopefulhttps://pharmaphorum.com/news/jj-pays-6-5bn-for-momenta-and-its-inflammatory-disease-hopeful/
Momenta rises thanks to its Copaxone challengerCompany is ready to launch three-times-weekly version of Teva’s drug Share XMomenta rises thanks to its Copaxone challengerhttps://pharmaphorum.com/news/momenta-rises-thanks-copaxone-challenger/